Expertise in
4
conditions

Inge M. Van Der Sluis-Van Der Pluijm

Utrecht, UT, NL 
Expertise in
4
conditions
Utrecht, UT, NL 

Overview

Inge Van Der Sluis-Van Der Pluijm practices practicing medicine in Utrecht, Netherlands.

Ms. Van Der Sluis-Van Der Pluijm is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Childhood Pancreatitis, and Peripheral Neuropathy.

She is actively involved in clinical research, co-authoring 101 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Utrecht, UT, Netherlands
Other Locations
Rotterdam, ZH, Netherlands
Bilthoven, UT 3720AC, Netherlands
The Hague, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

101 Total Publications

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.
Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.
Journal: Pediatric blood & cancer
Published: June 01, 2026

Frequently Asked Questions about Inge M. Van Der Sluis-Van Der Pluijm

Is Inge M. Van Der Sluis-Van Der Pluijm a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Inge M. Van Der Sluis-Van Der Pluijm is classified as an Distinguished expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Inge M. Van Der Sluis-Van Der Pluijm participate in research or clinical trials?

Yes. Inge M. Van Der Sluis-Van Der Pluijm has published 101 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Inge M. Van Der Sluis-Van Der Pluijm's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Van Der Sluis-Van Der Pluijm's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile